Acepodia

Acepodia is developing first-in-class, allogeneic cell therapies using its proprietary Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. Founded in 2017 with deep roots in Nobel laureate Carolyn Bertozzi's lab, the company has advanced multiple programs into Phase 1 clinical trials for oncology and autoimmune indications and secured strategic partnerships with industry leaders like Pfizer. Its strategy leverages a unique chemical conjugation approach to create readily available 'immune cell engagers' targeting both hematologic malignancies and solid tumors, aiming to democratize cell therapy access.

Proprietary Antibody-Cell Conjugation (ACC) platform using bioorthogonal click chemistry to attach targeting antibodies directly to immune cells (e.g., γδ2 T cells) without genetic engineering, creating off-the-shelf 'immune cell engagers.'

Acepodia competes with allogeneic cell therapy companies using gene-editing (e.g., Allogene, Caribou) and other γδ T cell-focused biotechs (e.g., Adicet). Its key differentiator is its non-genetic, chemical conjugation approach, which may offer manufacturing and flexibility advantages. In the ADC space, its AD2C platform faces entrenched competitors like Seagen and Daiichi Sankyo.